Key statistics
As of last trade Resmed Inc (RMD:NYQ) traded at 251.88, -1.29% below its 52-week high of 255.18, set on Sep 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 249.76 |
---|---|
High | 252.91 |
Low | 248.76 |
Bid | 251.80 |
Offer | 251.95 |
Previous close | 248.93 |
Average volume | 898.06k |
---|---|
Shares outstanding | 146.93m |
Free float | 145.76m |
P/E (TTM) | 35.97 |
Market cap | 36.58bn USD |
EPS (TTM) | 6.92 USD |
Annual div (ADY) | 2.12 USD |
---|---|
Annual div yield (ADY) | 0.85% |
Div ex-date | Aug 15 2024 |
Div pay-date | Sep 19 2024 |
Data delayed at least 15 minutes, as of Sep 16 2024 18:24 BST.
More ▼
- ResMed to Host Its 2024 Investor Day on September 30, 2024, at the New York Stock Exchange
- Vaping Expected to Increase COPD Health and Economic Burden by 2050
- ResMed Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
- ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board
- ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024
- ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
- PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
- Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
- ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
- ResMed Announces Participation in the RBCCM Global Healthcare Conference
More ▼